Pejkovska, Sava
Preferred name
Pejkovska, Sava
Official Name
Pejkovska, Sava
Translated Name
Пејковска С.
Alternative Name
S.Pejkovska
Pejkovska S.
Sava Pejkovska
Sava, Pejkovska
Пејковска С.
С.Пејковска
Пејковска Сава
Сава Пејковска
Main Affiliation
39 results
Now showing 1 - 10 of 39
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Role and Significance of Markers of Inflammation in the Asthmatic Disease(ID Design 2012/Scientific Foundation SPIROSKI, 2015-12-15) ;Goseva, Zlatica ;Jovanovska Janeva, Elena ;Gjorcev, Angelko; BACKGROUND: Asthma is characterized by airway inflammation which can be reversible. AIM: Investigation the importance of eosinophils, ECP and IL-5 in asthmatics versus patients with obstructive bronchitis and healthy subjects. We investigated the values before and after the treatment in asthmatics. MATERIAL AND METHODS: We studied 77 subjects divided in three groups as follows: 1) asthma patients; 2) patients with obstructive bronchitis and 3) control group of healthy subjects. In all the subjects there were determined: Total number of eosinophils (Eo), eosinophilic cationic protein (ECP), Interleukin 5 (IL-5) and allergy tests. RESULTS: The total number of eosinophils was significantly increased in the group of asthma patients versus second and third group. We found that the presence of ECP demonstrate an ongoing inflammation, with or without clinical symptoms of asthma patients. There was significant difference between the values of ECP of asthma patients versus second and third group. Our results have shown that IL-5 was significantly increased versus second group and controls (p < 0.01). We also found the decrease of the values of inflammatory markers after the treatment with corticosteroids. CONCLUSIONS: Eosinophils, ECP and IL-5 could be useful markers for selecting allergic patients and could be the monitors of treatment effects - Some of the metrics are blocked by yourconsent settings
Item type:Publication, BODY MASS INDEX AS A DETERMINANT OF OUTCOME OF TREATMENT WITH NON-INVASIVE VENTILATION IN PATIENTS WITH RESPIRATORY FAILURE DUE TO ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE(Macedonian Association of Anatomists and Morphologists, 2015-12); ; ;Goseva Z; Arbutina SIntroduction: In the last two decades noninvasive ventilation (NIV) has become an integral part of the protocol for the treatment of patients with acute respiratory failure. Aim of the study: To assess the relationship between body mass index (BMI) and outcome of treatment with NIV in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Material and methods: A total of 52 patients, over the age of 40, hospitalized because of acute exacerbation of COPD and treated with NIV were prospectively recruited. The patients were divided into two groups: 1) successful NIV treatment group; 2) failed NIV treatment group. Results: There was no significant difference in distribution between the two patients groups in terms of sex and age. Compared to group 1, in the group 2, difference was observed in the values of GCS that were lower, and the PaCO2 and APACHE II scores were higher, but the difference between the two groups was not significant (p> 0.05). Significant difference was observed between the values of pH (p <0.05) and BMI (p <0.01). The majority of patients with NIV treatment failure were with BMI <22kg / m2. Conclusion: The degree of acidosis and BMI are factors of statistical significance for the outcome of NIV treatment. Further studies are needed to clarify the reasons for the association between NIV and low BMI. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, The rationality of the use of NIV in elderly patients with acute COPD exacerbation(European Respiratory Society, 2018-09-15); ; ; ; Jovanoski, Smilko - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Predictive Factors for the Effect of Treatment by Noninvasive Ventilation in Patients with Respiratory Failure as a Result of Acute Exacerbation of the Chronic Obstructive PulmonaryDisease(ID Design 2012/Scientific Foundation SPIROSKI, 2015-11-11); ; ;Goseva Z.; Jovanovska Janeva E.BACKGROUND: Noninvasive mechanical ventilation (NIV) applies ventilator support through the patient’s upper airway using a mask. AIM: The aim of the study is to define factors that will point out an increased risk of NIV failure in patients with exacerbation of Chronic Obstructive Pulmonary Disease (COPD). PATIENTS AND METHODS: Patients over the age of 40, treated with NIV, were prospectively recruited. After data processing, the patients were divided into two groups: 1) successful NIV treat-ment group; 2) failed NIV treatment group.RESULTS: On admission arterial pH and Glasgow coma scale (GCS) levels were lower (pH: p<0.05, GCS: p<0.05), and Acute Physiology and Chronic Health Evaluation II (APACHE) score and PaCO2were higher (p<0.05) in the NIV failure group. Arterial pH was lower (p<0.05) and PaCO2and respiratory rate were higher (p<0.05) after 1h, and arterial pH was lower (p<0.05) and PaCO2(p<0.05), respiratory and heart rate were higher (p<0.05) after 4h in the NIV failure group.CONCLUSION: Measurement and monitoring of certain parameters may be of value in terms of predicting the effectiveness of NIV treatment.IntroductionChronic Obstructive Pulmonary disease (COPD) is one of the commonest diseases in the world. It is an increasing international health problem with a projected third leading cause of mortality within the adult population[1]. Chronic obstructive pulmo-nary disease is a respiratory disorder largely caused by smoking, and is characterized by progressive, par-tially reversible airway obstruction and lung hyperinfla-tion, systemic manifestations, and increasing fre-quency and severity of exacerbations. An acute exac-erbation is defined as a sustained worsening of dysp-nea, cough or sputum production leading to an in-crease in the use of maintenance medications and/or supplementation with additional medications[2]. The management of the acute exacerbations of COPD accounts for a large proportion of the health care costs because of the need for prolonged hospitaliza-tions and increased rate of mortality[3]. An important event in the course of the disease is the shortening of the inspiratory time, leading to a decrease of the Total Lung Capacity (TLC) and increase of the respiratory rate. The management which aims to increase the TLC with subsequent increase in the alveolar ventila-tion, as well as the decrease of the respiratory rate, is expected to reverse the impaired respiratory physiolo-gy[4]. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Systemic inflammatory profile in patients with chronic obstructive pulmonary disease(Macedonian Association of Anatomists and Morphologists, 2024-05-01) ;Debreshlioska, Angjela; ; ; Chronic obstructive pulmonary disease(COPD)is heterogeneous condition with various phenotypes that have their own pathogenetic mechanisms and certain inflammatory mediators, as C-reactive protein, interleukins, circulating leukocytes. Uncovering the inflammatory profile may identify disease biomarkers. We aimedto compare the values of systemic inflammatory parameters in patients with different clinical phenotypes and determine their correlation with clinical parameters.In 30 COPD patients weanalyzeddemographic and clinical data, history of allergies, cigarette smoking and history of exacerbations. We phenotyped them intonon-exacerbator, exacerbator and COPD with asthma phenotype. COPD assessment test, modified dyspnea scale and the BODE (Body mass index, Obstruction, Dyspnea, Exercise capacity) index werecalculated. Spirometry and lung X-ray were performed. Peripheral blood was taken for analysis of inflammatory parameters.There were 16 patients(53.33%) with phenotype of non-exacerbator, and 7 (23.33%) with exacerbatorand COPD with asthma phenotype each. COPD assessment testhadsignificantly lowestvalue in non-exacerbator and modified dyspnea scalesignificantly highest value in exacerbatorphenotype. Therewere no mild gradepatientsin exacerbator,andno very severe grade in nonexacerbatorphenotype. C-reactive proteinand interleukin 8 had significantly lowest value in non-exacerbator; leucocytes significantly highest value in exacerbator; eosinophyls and interleukin 4 significantly highest value in COPD with asthma phenotype. There was no significant difference among the three phenotypes in neutrophyls andinterleukin 18. The three clinical phenotypes: non-exacerbator, exacerbator and COPDwith asthma have their own specific clinical and inflammatory features that have clinical, prognostic and therapeutic implications - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Analysis of Lymphocyte Immunological Reactivity in Patients with Pleural Effusions of Different Aetiology(ID Design 2012/Scientific Foundation SPIROSKI, 2016-03-15) ;Goseva, Zlatica; ;Gjorcev, Angelko ;Jovanovska Janeva, ElenaBACKGROUND: The proportion of T and B lymphocytes in pleural fluids and blood may point to the presence of local immunological phenomena in pleural disorders.AIM: Aim of study was to evaluate the lymphocyte phenotype and the ratio between helper (CD4+) and cytotoxic/suppressor (CD8+) lymphocytes in malignant and non-malignant effusions.MATERIAL AND METHODS: We studied 48 patients with pleural effusions. First group had 18 patients with tuberculosis pleural effusions; second group had 20 patients with malignant pleural fluids, third group had 10 patients with transudates and 30 healthy controls. We investigated the distribution of T and B lymphocytes, T cells with helper/inducer CD4 or suppresser/cytotoxic CD8 phenotypes and the CD16 subset.RESULTS: Results showed decreases levels ofCD3, CD4, and CD16 T cells in blood of patients versus healthy controls. There were increases in the percentage of the CD3 and CD4 T cells in the pleural fluid compared with values in the blood with statistical significance in tuberculous pleurisy. The values of CD8 were similar in the pleural fluid and in blood. Levels of CD16 were non-significantly higher in pleural fluid in all groups.CONCLUSION: This study confirms the hypothesis that pleural cavity is compartment with immunological reactivity and results could be used in differential diagnosis together with other examinations.IntroductionLymphocytes are the primary effectors of cellular and humoral immunocompetence in humans. Lymphocytic pleural effusions are characterized by divergent cellular responses depending on the etiology of disease[1]. The accumulation of fluid in the pleural space indicates the presence of systemic or local disease. Pleural exudates involve the migration of immune cells to the pleural cavity[2]. Lymphocytes dominance occurs in the most chronic pleural effusions[3, 4]. The proportion of T and B lymphocytes in pleural fluids relative to that in peripheral blood may point to the presence of local immunological phenomena in various pulmonary and pleural disorders. Tuberculosis and malignant disease are among most frequent causes of pleural effusions. In both causes, the pleural fluid is generally lymphocytic, with predominance of T lymphocytes, particularly CD4+ positive T cells[2, 5, 6]. Malignant effusions are a relatively easily accessible source of tumor-associated T cells andthis represent a suitable model for the study of interactions between tumor cells and the host immune system[7]. Considering the compartmentalization of the pleural space, the association between the local and systemic cellular responses should be analyzed. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Correlation between detected respiratory pathogens and lung function in patients with acute exacerbation of chronic obstructive pulmonary disease(Македонско лекарско друштво = Macedonian medical association, 2021); ; ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Pulmonary embolism - Pulmonary thromboembolism in patient with rectal adenocarcinoma(Association of Traditional Chinese Medicine and Acupuncture Tong Da Tang TCM, Skopje R.N. Macedonia, 2024); ; ;Suzana Arbutina ;Gabrijela DimoskaAleksandra StefanovskaPulmonary thromboembolism (PTE) is potentially life-threatening disorder. The pathogenesis of pulmonary thromboembolism isn’t fully understood, but it is believed to involve imbalance between pro-coagulants and anticoagulants, as well as endothelial dysfunction and acute or chronic inflammation. Pulmonary embolism (PE) occurs when there is a disruption to the blood flow in the pulmonary artery or pulmonary branches by a thrombus that originated somewhere else. Risk factors for PE are deficiency of protein S,protein C deficiency, anti-thrombin III deficiency, LA-lupus anticoagulant, factor V Leiden deficiency, antiphospholipid syndrome (APLS), previous surgical treatment, chemotherapy, immunosuppressive drugs, immobility, overweight ,oral contraceptives, pregnancy ,history of vein thrombosis ,thrombophlebitis , varicose veins. There is a relationship between higher body mass index (BMI) and VTE, and patients with severe obesity (BMI ≥ 35) have higher risk of pulmonary thromboembolism compared with those of normal BMI. Patients with pulmonary thromboembolism may present with a spectrum of symptoms, including chest pain, shortness of breath, tachycardia, hemoptysis, asymmetric pitting edema on legs, prominent superficial collateral vessels, tenderness and pain to palpation of the leg, red or purple color, warmth on the affected leg. The diagnostic work-up of suspected pulmonary embolism includes D-dimer testing, ECG, ultrasonography of heart and CT angiography. Direct oral anticoagulants are first-line treatment options for venous thromboembolism because they are associated with a lower risk of bleeding disorders than vitamin K antagonists. Use of thrombolysis should be limited to pulmonary embolism associated with haemodynamic instability. Anticoagulants should be continued for at least 3 to 6 months to prevent early recurrences and relaps of PE. Haematological malignancies, lymphoma, lung cancers and colorectal cancers are the most common cause of PE - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Efficacy of herbal medicines in treatment of respiratory infections(Macedonian Association of Anatomists and Morphologists, 2024-10-24); ;Stoshevski, Bojan; ;Poposka, BiljanaNakova Krstikj, OliveraIntroduction. Herbal medicine forms the basis of modern pharmacy, and hence, it has much to offer to patients suffering from common, acute bronchitis and flu. The aim of this study was to investigate the efficacy of the herbal medicines Broncho Protect and Andrographis Extract as dietary supplements against standard medical treatment in patients with proven acute upper and/or lower respiratory tract infection. Thisprospective, double-blind, randomization study was conducted at the PHI University Clinic for Pulmonology and Allergology in Skopje. Forty patients with clinical symptoms of acute upper and/or lower respiratory tract infection were included. Patients were randomized into two groups; the first group received standard therapy without restrictions plus placebo and the second group which, in addition to standard therapy, received Bronho Protect and Andographis extract. The results of patients' self-assessment of their health status indicated a statistically significant improvement in both groups, but no difference in the final outcome. The results of the assessment of patients’ health status by the doctors indicated that in the group that received herbal medicines all patients gotbetter. Also, auscultation findings were significantly better in patients who were treated with herbal medicines. Herbal medicines are effective in treatment and prevention of respiratory infections and provide a much-needed alternative to ineffective antibiotics, whereby patients feel they are receiving beneficial therapy, thus reducing their tendency to use antibiotics. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Хроничен риносинузитис кај пациенти со астма и поврзаноста помеѓу синоназалната и бронхијална инфламација(Македонско лекарско друштво = Macedonian medical association, 2019-09) ;М. Милетиќ Ѓореска ;В. А. Груева Каранфилова; ;А. ДебрешлиоскаИ. Исмаили
